{"analyses":[{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.73","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.56","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"127"}],"title":"Disease progression"},{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"39"}],"title":"Without progression"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"166"}],"units":"Participants"}],"description":"Number of patients with disease progression or death","groups":[{"description":"Patients receive oral thalidomide daily and oral prednisone every other day for 4 years in the absence of disease progression or unacceptable toxicity.\n\nprednisone: Given orally\n\nthalidomide: Given orally","id":"OG000","title":"Prednisone"},{"description":"Patients undergo observation.","id":"OG001","title":"Observation"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intention-to-treat","reportingStatus":"POSTED","timeFrame":"9 years","title":"Disease Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Participants"}